Gilead HCV sales continue to weaken

Gilead Sciences Inc. (NASDAQ:GILD) slipped $1.69 to $66.90 in after-hours trading after it said HCV sales continued to decline in 1Q17 and reiterated its full-year guidance. The company missed quarterly earnings and revenue estimates.

The guidance, which incorporated fewer patient starts for blockbusters Harvoni ledipasvir/sofosbuvir and Sovaldi sofosbuvir, fell far short of investors' expectations when the company issued it in February (see BioCentury Extra, Feb. 7)...